SG11201809560QA - Enhancer of zeste homolog 2 inhibitors - Google Patents
Enhancer of zeste homolog 2 inhibitorsInfo
- Publication number
- SG11201809560QA SG11201809560QA SG11201809560QA SG11201809560QA SG11201809560QA SG 11201809560Q A SG11201809560Q A SG 11201809560QA SG 11201809560Q A SG11201809560Q A SG 11201809560QA SG 11201809560Q A SG11201809560Q A SG 11201809560QA SG 11201809560Q A SG11201809560Q A SG 11201809560QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- collegeville
- rule
- road
- applicant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
WO 17 / 19 15 45 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 09 November 2017 (09.11.2017) WIPO I PCT omit IIl mum 0 mu OH 100 oimIE (10) International Publication Number WO 2017/191545 Al (51) International Patent Classification: C07D 495/04 (2006.01) (21) International Application Number: (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1 7(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.1 7(iii)) of inventorship (Rule 4.1 7(iv)) PCT/IB2017/052523 (22) International Filing Date: 01 May 2017 (01.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/332,131 05 May 2016 (05.05.2016) US 62/359,904 08 July 2016 (08.07.2016) US 62/454,143 03 February 2017 (03.02.2017) US 62/482,964 07 April 2017 (07.04.2017) US (71) Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED [GB/GB]; 980 Great West Road, Brentford Middlesex TW89GS (GB). (72) Inventors: KNIGHT, Steven David; 1250 South Col- legeville Road, Collegeville, Pennsylvania 19426 (US). LAFRANCE, III, Louis Vincent; 1250 South Collegeville Road, Collegeville, Pennsylvania 19426 (US). TIAN, Xin- rong; 1250 South Collegeville Road, Collegeville, Pennsyl- vania 19426 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Published: with international search report (Art. 21(3)) (54) Title: ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS (57) : This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical com- positions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers. R 2 L-. R3 (I)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332131P | 2016-05-05 | 2016-05-05 | |
| US201662359904P | 2016-07-08 | 2016-07-08 | |
| US201762454143P | 2017-02-03 | 2017-02-03 | |
| US201762482964P | 2017-04-07 | 2017-04-07 | |
| PCT/IB2017/052523 WO2017191545A1 (en) | 2016-05-05 | 2017-05-01 | Enhancer of zeste homolog 2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809560QA true SG11201809560QA (en) | 2018-11-29 |
Family
ID=58709513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809560QA SG11201809560QA (en) | 2016-05-05 | 2017-05-01 | Enhancer of zeste homolog 2 inhibitors |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10604531B2 (en) |
| EP (1) | EP3452483B1 (en) |
| JP (1) | JP2019516685A (en) |
| KR (1) | KR20190003699A (en) |
| CN (1) | CN109328188A (en) |
| AU (1) | AU2017260854B2 (en) |
| BR (1) | BR112018072740A2 (en) |
| CA (1) | CA3023157A1 (en) |
| CL (1) | CL2018003121A1 (en) |
| CO (1) | CO2018011819A2 (en) |
| CR (1) | CR20180521A (en) |
| DO (1) | DOP2018000238A (en) |
| ES (1) | ES2801423T3 (en) |
| IL (1) | IL262701A (en) |
| MX (1) | MX2018013519A (en) |
| PE (1) | PE20190106A1 (en) |
| PH (1) | PH12018502314A1 (en) |
| SG (1) | SG11201809560QA (en) |
| TW (1) | TW201806955A (en) |
| UY (1) | UY37225A (en) |
| WO (1) | WO2017191545A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| CN111757734A (en) * | 2017-12-28 | 2020-10-09 | 星座制药公司 | Pharmacokinetic enhancement of EZH2 inhibitors by combination therapy |
| NZ766447A (en) | 2018-01-31 | 2021-12-24 | Mirati Therapeutics Inc | Prc2 inhibitors |
| CN112399857A (en) | 2018-07-09 | 2021-02-23 | 盲人庇护基金会 | Inhibition of PRC2 subunit for the treatment of ocular disorders |
| CN111537654B (en) * | 2020-07-07 | 2020-11-10 | 上海亚盛医药科技有限公司 | HPLC analysis method of N- (phenylsulfonyl) benzamide compound |
| CN112830957B (en) * | 2021-01-07 | 2022-07-22 | 江西师范大学 | Method for preparing carfilzomib |
| WO2024089216A1 (en) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Novel sulfur-containing heteroaryl carboxamide compounds |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB427857A (en) | 1934-08-02 | 1935-05-01 | Newsum Sons & Company Ltd H | A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| JP3871503B2 (en) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | Immune disease treatment |
| JP4210454B2 (en) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | Inflammatory bowel disease treatment |
| CN1606446A (en) | 2000-05-19 | 2005-04-13 | 科里克萨有限公司 | Method for preventing and treating communicable diseases and other diseases using monosaccharides and disaccharides |
| WO2002012258A1 (en) | 2000-08-04 | 2002-02-14 | Corixa Corporation | New immunoeffector compounds |
| JP4212278B2 (en) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | Graft rejection inhibitor |
| US7285552B2 (en) | 2001-03-19 | 2007-10-23 | Ono Pharmaceuticals Co., Ltd. | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient |
| US6525028B1 (en) | 2002-02-04 | 2003-02-25 | Corixa Corporation | Immunoeffector compounds |
| US6911434B2 (en) | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
| IL164376A0 (en) | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
| CA2489004C (en) | 2002-06-13 | 2013-01-08 | Crucell Holland B.V. | Agonistic binding molecules to the human ox40 receptor |
| EP2243493A1 (en) | 2002-07-03 | 2010-10-27 | Ono Pharmaceutical Co., Ltd. | Immunopotentiative composition |
| MXPA05006828A (en) | 2002-12-23 | 2005-09-08 | Wyeth Corp | Antibodies against pd-1 and uses therefor. |
| US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
| EP2270051B1 (en) | 2003-01-23 | 2019-05-15 | Ono Pharmaceutical Co., Ltd. | Antibody specific for human PD-1 and CD3 |
| SI2161336T1 (en) | 2005-05-09 | 2013-11-29 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| BRPI0613361A2 (en) | 2005-07-01 | 2011-01-04 | Medarex Inc | isolated human monoclonal antibody, composition, immunoconjugate, bispecific molecule, isolated nucleic acid molecule, expression vector, host cell, transgenic mouse, method for modulating an immune response in an individual, method for inhibiting tumor cell growth in an individual, method for treating an infectious disease in a subject, a method for enhancing an immune response to an antigen in a subject, a method for treating or preventing an inflammatory disease in a subject, and a method for preparing the anti-pd-11 antibody |
| WO2008137915A2 (en) | 2007-05-07 | 2008-11-13 | Medimmune, Llc | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| EP3239178A1 (en) | 2007-12-14 | 2017-11-01 | Bristol-Myers Squibb Company | Binding molecules to the human ox40 receptor |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| US20110223188A1 (en) | 2008-08-25 | 2011-09-15 | Solomon Langermann | Targeted costimulatory polypeptides and methods of use to treat cancer |
| AU2009296392B2 (en) | 2008-09-26 | 2016-06-02 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
| EP2358392B1 (en) | 2008-11-12 | 2019-01-09 | MedImmune, LLC | Antibody formulation |
| KR20210060670A (en) | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| BR122021025338B1 (en) | 2009-11-24 | 2023-03-14 | Medimmune Limited | ISOLATED ANTIBODY OR BINDING FRAGMENT THEREOF AGAINST B7-H1, PHARMACEUTICAL COMPOSITION AND ITS USES |
| US20110280877A1 (en) | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
| CN103221427B (en) | 2010-08-23 | 2016-08-24 | 德克萨斯州立大学董事会 | Anti-OX40 antibody and the method using it |
| EP3147297B1 (en) | 2011-03-31 | 2018-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies directed against icos and uses thereof |
| JO3438B1 (en) | 2011-04-13 | 2019-10-20 | Epizyme Inc | Aryl- or heteroaryl-substituted benzene compounds |
| WO2013019906A1 (en) | 2011-08-01 | 2013-02-07 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| KR101685262B1 (en) | 2011-08-23 | 2016-12-21 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | Anti-ox40 antibodies and methods of using the same |
| HUE051954T2 (en) | 2011-11-28 | 2021-03-29 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| KR101947702B1 (en) | 2012-10-04 | 2019-02-14 | 다나-파버 캔서 인스티튜트 인크. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| UA111305C2 (en) * | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Condensed with lactams of aryl and heteroaryl |
| CA2910873A1 (en) | 2013-04-30 | 2014-11-06 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| PE20161552A1 (en) | 2014-06-17 | 2017-01-11 | Pfizer | SUBSTITUTE DIHYDROISOQUINOLINONE COMPOUNDS |
| RU2017118165A (en) * | 2014-10-28 | 2018-11-29 | Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед | Homolog Enhancer 2 Zestes Inhibitors |
| TW201636344A (en) | 2014-12-05 | 2016-10-16 | 美國禮來大藥廠 | Inhibitors of EZH2 |
| UY36758A (en) * | 2015-06-30 | 2016-12-30 | Glaxosmithkline Ip No 2 Ltd | INHIBITORS OF THE ZESTE 2 HOMOLOGIST POTENTIATOR |
| TW201718598A (en) * | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Inhibitors of EZH2 |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
-
2017
- 2017-05-01 CN CN201780038943.5A patent/CN109328188A/en active Pending
- 2017-05-01 US US16/097,322 patent/US10604531B2/en not_active Expired - Fee Related
- 2017-05-01 JP JP2018557862A patent/JP2019516685A/en active Pending
- 2017-05-01 CA CA3023157A patent/CA3023157A1/en not_active Abandoned
- 2017-05-01 PE PE2018002174A patent/PE20190106A1/en unknown
- 2017-05-01 EP EP17723766.6A patent/EP3452483B1/en active Active
- 2017-05-01 AU AU2017260854A patent/AU2017260854B2/en not_active Ceased
- 2017-05-01 CR CR20180521A patent/CR20180521A/en unknown
- 2017-05-01 WO PCT/IB2017/052523 patent/WO2017191545A1/en unknown
- 2017-05-01 KR KR1020187034784A patent/KR20190003699A/en not_active Application Discontinuation
- 2017-05-01 BR BR112018072740-7A patent/BR112018072740A2/en not_active IP Right Cessation
- 2017-05-01 SG SG11201809560QA patent/SG11201809560QA/en unknown
- 2017-05-01 ES ES17723766T patent/ES2801423T3/en active Active
- 2017-05-01 MX MX2018013519A patent/MX2018013519A/en unknown
- 2017-05-03 UY UY0001037225A patent/UY37225A/en unknown
- 2017-05-03 TW TW106114574A patent/TW201806955A/en unknown
-
2018
- 2018-10-31 CL CL2018003121A patent/CL2018003121A1/en unknown
- 2018-10-31 DO DO2018000238A patent/DOP2018000238A/en unknown
- 2018-10-31 CO CONC2018/0011819A patent/CO2018011819A2/en unknown
- 2018-10-31 IL IL262701A patent/IL262701A/en unknown
- 2018-11-05 PH PH12018502314A patent/PH12018502314A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN109328188A (en) | 2019-02-12 |
| CO2018011819A2 (en) | 2018-11-22 |
| CR20180521A (en) | 2019-01-15 |
| DOP2018000238A (en) | 2019-10-31 |
| PH12018502314A1 (en) | 2019-04-15 |
| KR20190003699A (en) | 2019-01-09 |
| ES2801423T3 (en) | 2021-01-11 |
| UY37225A (en) | 2017-11-30 |
| EP3452483A1 (en) | 2019-03-13 |
| AU2017260854B2 (en) | 2020-01-30 |
| IL262701A (en) | 2018-12-31 |
| BR112018072740A2 (en) | 2019-02-19 |
| EP3452483B1 (en) | 2020-04-01 |
| CL2018003121A1 (en) | 2018-12-14 |
| PE20190106A1 (en) | 2019-01-15 |
| TW201806955A (en) | 2018-03-01 |
| CA3023157A1 (en) | 2017-11-09 |
| US20190092785A1 (en) | 2019-03-28 |
| AU2017260854A1 (en) | 2018-11-15 |
| WO2017191545A1 (en) | 2017-11-09 |
| MX2018013519A (en) | 2019-03-14 |
| JP2019516685A (en) | 2019-06-20 |
| US10604531B2 (en) | 2020-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809560QA (en) | Enhancer of zeste homolog 2 inhibitors | |
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201808708RA (en) | Heterocyclic amides useful as protein modulators | |
| SG11201809625RA (en) | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
| SG11201810834WA (en) | Hepatitis b antiviral agents | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201808220VA (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201407988UA (en) | Process for improved opioid synthesis | |
| SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions | |
| SG11201809172WA (en) | Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |